Authors:
Kluin-Nelemans, HC
Zagonel, V
Anastasopoulou, A
Bron, D
Roozendaal, KJ
Noordijk, EM
Musson, H
Teodorovic, I
Maes, B
Carbone, A
Carde, P
Thomas, J
Citation: Hc. Kluin-nelemans et al., Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study, J NAT CANC, 93(1), 2001, pp. 22-30
Authors:
Girinsky, T
Guillot-Vals, D
Koscielny, S
Cosset, JM
Ganem, G
Carde, P
Monhonval, M
Pereira, R
Bosq, J
Ribrag, V
Vantelon, JM
Munck, JN
Citation: T. Girinsky et al., A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: Analysis of predictive parameters of response to treatment, INT J RAD O, 51(1), 2001, pp. 148-155
Authors:
Vantelon, JM
Munck, JN
Bourhis, JH
Pico, JL
Fadel, C
Ulusakarya, A
Carde, P
Fenaux, P
Ribrag, V
Citation: Jm. Vantelon et al., Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy, BONE MAR TR, 27(5), 2001, pp. 531-536
Authors:
Carde, P
Timmerman, R
Mehta, MP
Koprowski, CD
Ford, J
Tishler, RB
Miles, D
Miller, RA
Renschler, MF
Citation: P. Carde et al., Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases, J CL ONCOL, 19(7), 2000, pp. 2074-2083
Authors:
Viala, J
Vanel, D
Meingan, P
Lartigau, E
Carde, P
Renschler, M
Citation: J. Viala et al., Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases, RADIOLOGY, 212(3), 1999, pp. 755-759